FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783013682> ?p ?o ?g. }

• W2783013682 endingPage "1280" @default.
• W2783013682 startingPage "1275" @default.
• W2783013682 abstract "¹⁸F-(<i>E</i>)-<i>N</i>-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4′-methyl-phenyl) nortropane (¹⁸F-FE-PE2I) was recently developed and has shown adequate affinity and high selectivity for the dopamine transporter (DAT). Previous studies have shown promising results for ¹⁸F-FE-PE2I as a suitable radioligand for DAT imaging. In this study, we investigated the whole-body biodistribution and dosimetry of ¹⁸F-FE-PE2I in healthy volunteers to support its utility as a suitable PET imaging agent for the DAT. <b>Methods:</b> Five healthy volunteers were given a mean activity of 2.5 MBq/kg, and 3 PET scans, head to thigh, were performed immediately after injection followed by 4 whole-body PET/CT scans between 0.5 and 6 h after injection. Blood samples were drawn in connection with the whole-body scans, and all urine was collected until 6 h after injection. Volumes of interest were delineated around 17 organs on all images, and the areas under the time–activity curves were calculated to obtain the total number of decays in the organs. The absorbed doses to organs and the effective dose were calculated using the software IDAC. <b>Results:</b> The highest activity concentration was observed in the liver (0.9%–1.2% injected activity/100 g) up to 30 min after injection. At later time points, the highest concentration was seen in the gallbladder (1.1%–0.1% injected activity/100 g). The activity excreted with urine ranged between 23% and 34%, with a mean of 28%. The urinary bladder received the highest absorbed dose (119 μGy/MBq), followed by the liver (46 μGy/MBq). The effective dose was 23 μSv/MBq (range, 19–28 μSv/MBq), resulting in an effective dose of 4.6 mSv for an administered activity of 200 MBq. <b>Conclusion:</b> The effective dose is within the same order of magnitude as other commonly used PET imaging agents as well as DAT agents. The reasonable effective dose, together with the previously reported favorable characteristics for DAT imaging and quantification, indicates that ¹⁸F-FE-PE2I is a suitable radioligand for DAT imaging." @default.
• W2783013682 created "2018-01-26" @default.
• W2783013682 creator A5010172490 @default.
• W2783013682 creator A5026942684 @default.
• W2783013682 creator A5038261036 @default.
• W2783013682 creator A5052724050 @default.
• W2783013682 creator A5065002363 @default.
• W2783013682 creator A5076310194 @default.
• W2783013682 creator A5081327813 @default.
• W2783013682 creator A5083401517 @default.
• W2783013682 creator A5084783384 @default.
• W2783013682 date "2018-01-18" @default.
• W2783013682 modified "2023-09-29" @default.
• W2783013682 title "Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand ¹⁸F-FE-PE2I in Human Subjects" @default.
• W2783013682 cites W1899551010 @default.
• W2783013682 cites W1970453159 @default.
• W2783013682 cites W1982913371 @default.
• W2783013682 cites W1996925582 @default.
• W2783013682 cites W2012689648 @default.
• W2783013682 cites W2032654155 @default.
• W2783013682 cites W2037211078 @default.
• W2783013682 cites W2065374339 @default.
• W2783013682 cites W2084161441 @default.
• W2783013682 cites W2096574063 @default.
• W2783013682 cites W2105153214 @default.
• W2783013682 cites W2105586321 @default.
• W2783013682 cites W2124767905 @default.
• W2783013682 cites W2151908951 @default.
• W2783013682 cites W2155408421 @default.
• W2783013682 cites W2166263576 @default.
• W2783013682 cites W2315377180 @default.
• W2783013682 cites W2370777073 @default.
• W2783013682 cites W2405891631 @default.
• W2783013682 cites W4239173708 @default.
• W2783013682 doi "https://doi.org/10.2967/jnumed.117.197186" @default.
• W2783013682 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29348315" @default.
• W2783013682 hasPublicationYear "2018" @default.
• W2783013682 type Work @default.
• W2783013682 sameAs 2783013682 @default.
• W2783013682 citedByCount "12" @default.
• W2783013682 countsByYear W27830136822018 @default.
• W2783013682 countsByYear W27830136822020 @default.
• W2783013682 countsByYear W27830136822022 @default.
• W2783013682 countsByYear W27830136822023 @default.
• W2783013682 crossrefType "journal-article" @default.
• W2783013682 hasAuthorship W2783013682A5010172490 @default.
• W2783013682 hasAuthorship W2783013682A5026942684 @default.
• W2783013682 hasAuthorship W2783013682A5038261036 @default.
• W2783013682 hasAuthorship W2783013682A5052724050 @default.
• W2783013682 hasAuthorship W2783013682A5065002363 @default.
• W2783013682 hasAuthorship W2783013682A5076310194 @default.
• W2783013682 hasAuthorship W2783013682A5081327813 @default.
• W2783013682 hasAuthorship W2783013682A5083401517 @default.
• W2783013682 hasAuthorship W2783013682A5084783384 @default.
• W2783013682 hasBestOaLocation W27830136821 @default.
• W2783013682 hasConcept C104317684 @default.
• W2783013682 hasConcept C149011108 @default.
• W2783013682 hasConcept C170493617 @default.
• W2783013682 hasConcept C177322064 @default.
• W2783013682 hasConcept C185592680 @default.
• W2783013682 hasConcept C202751555 @default.
• W2783013682 hasConcept C2776755682 @default.
• W2783013682 hasConcept C2777807558 @default.
• W2783013682 hasConcept C2780026642 @default.
• W2783013682 hasConcept C2989005 @default.
• W2783013682 hasConcept C55493867 @default.
• W2783013682 hasConcept C67847695 @default.
• W2783013682 hasConcept C71924100 @default.
• W2783013682 hasConcept C75088862 @default.
• W2783013682 hasConceptScore W2783013682C104317684 @default.
• W2783013682 hasConceptScore W2783013682C149011108 @default.
• W2783013682 hasConceptScore W2783013682C170493617 @default.
• W2783013682 hasConceptScore W2783013682C177322064 @default.
• W2783013682 hasConceptScore W2783013682C185592680 @default.
• W2783013682 hasConceptScore W2783013682C202751555 @default.
• W2783013682 hasConceptScore W2783013682C2776755682 @default.
• W2783013682 hasConceptScore W2783013682C2777807558 @default.
• W2783013682 hasConceptScore W2783013682C2780026642 @default.
• W2783013682 hasConceptScore W2783013682C2989005 @default.
• W2783013682 hasConceptScore W2783013682C55493867 @default.
• W2783013682 hasConceptScore W2783013682C67847695 @default.
• W2783013682 hasConceptScore W2783013682C71924100 @default.
• W2783013682 hasConceptScore W2783013682C75088862 @default.
• W2783013682 hasIssue "8" @default.
• W2783013682 hasLocation W27830136821 @default.
• W2783013682 hasLocation W27830136822 @default.
• W2783013682 hasOpenAccess W2783013682 @default.
• W2783013682 hasPrimaryLocation W27830136821 @default.
• W2783013682 hasRelatedWork W1979441788 @default.
• W2783013682 hasRelatedWork W1987262526 @default.
• W2783013682 hasRelatedWork W2387755006 @default.
• W2783013682 hasRelatedWork W2508336498 @default.
• W2783013682 hasRelatedWork W2799682065 @default.
• W2783013682 hasRelatedWork W2954446054 @default.
• W2783013682 hasRelatedWork W2965802642 @default.
• W2783013682 hasRelatedWork W2995817629 @default.
• W2783013682 hasRelatedWork W4248152117 @default.
• W2783013682 hasRelatedWork W4323517738 @default.

• next